Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Several possible studies

Story checked

The Lowdown on Low-Dose Aspirin for Primary Prevention (opens in a new tab)

erictopol.substack.com · 2026-01-02

Short answerEvidenceSource

Short answer

Several possible studies

No clear answer.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Source paper

Source layer

The 5 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Related research

Research nearby

The papers it could be

Nearby papers when the source is unclear.

and 19 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 10Not checkedLow-dose aspirin is not safe and effective for primary prevention in healthy adults, especially people aged 60 years and older.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 10Not checkedIn 2018, three pivotal randomized trials consistently showed that the risk of major bleeding exceeded the benefit of cardiovascular event reduction.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 10Not checkedIn ASPREE, among healthy older adults, aspirin increased all-cause mortality, largely because of increased cancer mortality, and did not significantly reduce cardiovascular events; it also increased major bleeding.View evidenceHide evidence

As stated14% higher death rate; 31% increased hazard ratio for cancer mortality; major bleeding 8.6 vs 6.2 events per 1,000 person-years; HR 1.38

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 10Not checkedIn ASCEND, among people with diabetes but no evident cardiovascular disease, the reduction in vascular events was offset by more major bleeding.View evidenceHide evidence

As stated12% reduction in vascular events; 29% excess of major bleeding events

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 10Not checkedIn ARRIVE, among participants at moderate cardiovascular risk, enteric-coated aspirin did not reduce the first cardiovascular composite outcome and roughly doubled gastrointestinal bleeding.View evidenceHide evidence

As statedabout a doubling of gastrointestinal bleeding events

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 10Not checkedLong-term follow-up of ASPREE showed increased major adverse cardiovascular events and increased major bleeding in the aspirin group versus placebo.View evidenceHide evidence

As stated17% increase in major adverse cardiovascular events; 8% increase in major bleeding events

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 7 of 10Not checkedThe article says these trials led ACC/AHA and USPSTF to change recommendations, with age cutoffs against primary-prevention aspirin at 70+ years for ACC/AHA and 60+ years for USPSTF.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 8 of 10Not checkedFor special risk factors, the article says there are no data supporting primary-prevention low-dose aspirin for elevated Lp(a) in older adults, while elevated coronary artery calcium may help personalize aspirin use only in adults aged 40 to 70 and not at age 70+.View evidenceHide evidence

As statedCAC 400 or higher: 400 people treated for 5 years to prevent 1 event

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 9 of 10Not checkedThe article says aspirin may offer some modest cancer-prevention benefit in ASPREE-related analyses, but this remains uncertain and may depend on clonal hematopoiesis biomarkers not used in routine practice.View evidenceHide evidence

As stated100 mg aspirin provided some modest protection from developing cancer

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 10 of 10Not checkedThe overall conclusion is that low-dose aspirin should not be used for primary prevention in older adults without cardiovascular disease, while secondary prevention remains beneficial.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

Crossref, PubMed, Europe PMC · 20 candidate papers

And 15 more candidates considered.